Robert A Gasser, Jr

Title: Innovations by Robert A Gasser, Jr.

Introduction

Robert A Gasser, Jr. is an accomplished inventor based in Gaithersburg, MD (US). He holds two patents that focus on significant advancements in the field of biomarkers for IL23-mediated diseases, particularly Crohn's disease. His work has the potential to greatly impact patient treatment and outcomes.

Latest Patents

Gasser's latest patents include the use of CCL20 as a predictor of clinical response to IL23-antagonists. This invention relates to utilizing the Chemokine (C-C motif) ligand 20 (CCL20) as a biomarker to identify patients suffering from IL23-mediated diseases who are responsive to anti-IL23 treatment. The levels of CCL20 can help determine patient eligibility for treatment and predict treatment outcomes. Another significant patent involves the prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers such as IL22 and lipocalin-2 (LCN2). This invention also aims to stratify patients based on their response to treatment, enhancing the precision of therapeutic interventions.

Career Highlights

Throughout his career, Robert A Gasser, Jr. has worked with notable companies such as Amgen Inc. and Medimmune Limited. His experience in these organizations has contributed to his expertise in the field of biomedical research and innovation.

Collaborations

Gasser has collaborated with esteemed colleagues, including Robert W Georgantas, III and Chris Morehouse. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in the medical field.

Conclusion

Robert A Gasser, Jr. is a notable inventor whose work in biomarkers for IL23-mediated diseases is paving the way for improved patient care. His contributions to the field are significant and demonstrate the importance of innovation in medical research.